Currently, Adma Biologics Inc’s (ADMA) stock is trading at $14.51, marking a fall of -0.79% from last night’s close. At this price, the stock is -43.49% below its 52-week high of $25.67 and 7.44% above its 52-week low of $13.50. Based on the past 30-day period, the stock price is -12.96% below the high and +4.70% above the low.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, ADMA’s SMA-200 is $18.11.
As well, it is important to consider ADMA stock ratios such as price-to-sales, which is currently 7.30.Likewise, its price to free cash flow for the last twelve months stands at 52.63. ADMA’s price to book ratio for the most recent quarter was 8.72, resulting in an 38.34 price to cash per share for the period.
How does Adma Biologics Inc (ADMA) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 4 brokerage firms that recommend the stock as a Strong Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 4.50 in simple terms.
Adma Biologics Inc (ADMA): Earnings History
Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 1 different analysts, who are expecting earnings to fall in between the range of 0.16 and 0.16 with an average Earnings Estimate of 0.16 which is in contrast with the last year earnings estimate of 0.15 and also replicates 6.67% growth rate year over year.
Adma Biologics Inc (NASDAQ: ADMA) Ownership Details
I will give a breakdown of the key shareholders in Adma Biologics Inc (ADMA). Recent figures show that the company’s insiders hold 2.57% of shares. A total of 500 institutional investors hold shares in the company, making 90.62% of its stock and 93.01% of its float.
Aug 31, 2025, it was reported that the Company’s largest institutional holder is iShares Trust-iShares Core S&P Small-Cap ETF holding total of 14.2 shares that make 5.95% of the company’s total number of shares and are currently priced at 206.56 million.
The securities firm VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds 7.32 shares of ADMA, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 3.07%, and the holding percentage of shares is valued at 106.52 million.
An overview of Adma Biologics Inc’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Adma Biologics Inc (ADMA) traded 3,322,760 shares per day, with a moving average of $15.20 and price change of -1.64. With the moving average of $16.46 and a price change of -4.12, about 3,365,524 shares changed hands on average over the past 50 days. Finally, ADMA’s 100-day average volume is 3,084,905 shares, alongside a moving average of $17.70 and a price change of -5.22.
